Transperineal vs. Transrectal MRI-targeted Prostate Biopsy - Trial NCT04815876
Access comprehensive clinical trial information for NCT04815876 through Pure Global AI's free database. This phase not specified trial is sponsored by Weill Medical College of Cornell University and is currently Recruiting. The study focuses on Infection. Target enrollment is 1302 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Weill Medical College of Cornell University
Timeline & Enrollment
N/A
Jun 24, 2021
Apr 30, 2025
Primary Outcome
Change in infection adverse events, as measured on TRUS-BxQ
Summary
Approximately one million transrectal prostate biopsies are performed annually in the U.S.,
 and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of
 rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach
 under local anesthesia compared to the standard practice transrectal MRI-targeted prostate
 biopsy has a much lower risk of infection, comparable pain/discomfort and may improve
 detection of prostate cancer.
 
 This randomized controlled trial will be the first prospective study to evaluate in-office
 transperineal MRI targeted prostate biopsy.
 
 The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local
 anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a
 much lower risk of infection, comparable pain/discomfort and may improve detection of
 prostate cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04815876
Non-Device Trial